Investor Soleus Capital, LLC
13D/G Filings

This page shows a list of all the recent 13D/G filings made by Soleus Capital, LLC . Schedule 13D is commonly referred to as a “beneficial ownership report.” The term "beneficial owner" is defined under SEC rules. It includes any person who directly or indirectly shares voting power or investment power (the power to sell the security).

When a person or group of persons acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities, they are required to file a Schedule 13D within ten days after the purchase. Click the link icon to see the full transaction history.

Add This Fund
to your dashboard

Date Form Target Prev
Shares		 Current
Shares		 Change
(Percent)		 Ownership
(Percent)		 Change
(Percent)
2025-02-11 13G/A EPIX / ESSA Pharma Inc. 4,327,622 2,262,026
2024-01-23 13G/A EPIX / ESSA Pharma Inc. 3,869,392 4,327,622
2023-02-14 13G/A EPIX / ESSA Pharma Inc. 3,525,457 3,869,392
2022-02-10 13G/A DRIO / DarioHealth Corp. 401,606 0
2022-02-10 13G/A EPIX / ESSA Pharma Inc. 3,474,658 3,525,457
2021-02-12 13G/A EPIX / ESSA Pharma Inc. 2,844,187 3,474,658
2020-08-03 13G/A EPIX / ESSA Pharma Inc. 2,122,973 2,844,187
2020-07-31 13G DRIO / DarioHealth Corp. 401,606
2020-02-12 13G/A EPIX / ESSA Pharma Inc. 2,138,262 2,122,973
2019-08-29 13G EPIX / ESSA Pharma Inc. 2,138,262
2019-08-28 13G EPIX / ESSA Pharma Inc. 2,138,262